Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
about
AmbrisentanObesity paradox in group 1 pulmonary hypertension: analysis of the NIH-Pulmonary Hypertension registryMulticentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocolA pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial.Pulmonary hypertension: a guide for GPs.Identifying "super responders" in pulmonary arterial hypertension.Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study.Considerations for numerical modeling of the pulmonary circulation--a review with a focus on pulmonary hypertension.Pulmonary arterial hypertension associated with connective tissue disease: meta-analysis of clinical trialsEarly detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward.Treatment of pulmonary arterial hypertension with targeted therapies.Imatinib mesylate for the treatment of pulmonary arterial hypertension.Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden.The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease.Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.Update on pulmonary arterial hypertension pharmacotherapy.The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.Diagnosis, Treatment, and Clinical Management of Pulmonary Arterial Hypertension in the Contemporary Era: A Review.Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.Involvement of Ca2+-activated K+ channel 3.1 in hypoxia-induced pulmonary arterial hypertension and therapeutic effects of TRAM-34 in rats.Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in TaiwanHow prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension.Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition.Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension.Magnetic resonance imaging to assess the effect of exercise training on pulmonary perfusion and blood flow in patients with pulmonary hypertension.Stress Doppler echocardiography in systemic sclerosis: evidence for a role in the prediction of pulmonary hypertension.Search for an animal model to investigate selective pulmonary vasodilation.Altered synchrony of right ventricular contraction in borderline pulmonary hypertension.Interdependence of right ventricular systolic function and left ventricular filling and its association with outcome for patients with pulmonary hypertension.Exercise Training in Pulmonary Hypertension and Right Heart Failure: Insights from Pre-clinical Studies.Surgical treatment for adult congenital heart disease: consideration for indications and procedures.Randomized controlled trials: a solid platform for observational research.Medical therapies for pulmonary arterial hypertension.Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension.Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress.Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.Pulmonary Arterial Hypertension: Pathophysiology and Treatment.
P2860
Q28238985-AEB231B5-DF05-4171-9A1A-88C39FF2FEC9Q30274745-C3D05A39-7FCD-4424-A64F-B6C57288A708Q30490484-B92CA814-0DB3-404D-84B6-E42968B51C8EQ30539790-135EF876-B416-429D-875E-CFFEBB578F3DQ33162106-6C82CC5A-D816-4933-92EF-502077C30EF9Q33788452-E7F63667-AE77-4328-8EE9-5A37F8520E6CQ36721421-AE62C440-CB23-4DE8-AC17-44A303909DF9Q36995269-ACA515BF-CAC4-49A3-98E0-025D7B889F8EQ37069668-CF231453-8B82-481E-B433-D4732C8457FFQ37880493-1EF52436-3141-4FDB-9667-51265CE5DE7BQ37902509-12141E05-24DB-47A2-9830-8CD4F828FAE1Q37954724-3F811325-050F-4999-A64E-4D37D043A3D6Q38057110-119931F3-4A29-4363-A0B0-AA3ABB11CA95Q38124878-1A6AC254-3A38-4A28-A92F-31CF9C61798BQ38367248-8DD54C03-91A3-4A4A-BB3A-9BDFB8190A10Q38846020-5E709DCA-9D12-4AC8-A8AB-646153064DACQ39003465-877E4973-6A78-49FF-B291-DBABEBAA1DA5Q39010196-B4D6FEF4-E682-49DE-BFD7-29C8A5DD3AA1Q39042753-00012019-EABD-49F6-82F6-AC27548AE69CQ41138956-7AD3D64C-6EA1-4C79-B8E6-2C719DDA3BE0Q41669738-294B6AC8-2BEB-49BA-92CE-4056CB983391Q42357125-D386A348-849C-42A2-A88E-4C4B251F8102Q43885881-9B9320F3-82CF-43EB-8C4B-DC35E2FEFE14Q44070513-AA9A694B-1DBA-481D-B5DC-6E0D64B87A52Q45352755-9356AB41-B4E2-4376-89D7-91B4678FE3F2Q45960565-80BBC671-9718-4135-B1E6-CA71439BCF14Q45978370-4D768432-EAB5-4610-85E4-2832DFBC4F02Q46377829-3DFC1866-083A-4A68-A3F0-74A1B75976DAQ47360550-E0029E0A-6FAE-42BE-9234-C26024B93F97Q47945663-B026E3BE-AC83-4B51-8FF9-A845581F6BBBQ48363961-32A5A0B9-452A-4106-95C5-440E743965D5Q50096404-58F2BF4E-1690-408F-8997-24EE30A6F747Q50100551-A2F6497C-9489-4F0E-970B-C78819122AC7Q53786641-14E7D06B-6DD0-4A79-8F27-8C966217DD45Q53800780-38349255-6509-466A-9FAB-4000BFD1BE62Q54352901-384A3F54-9FE0-417F-88C3-064BB529F4C3Q54370056-F89154C0-EC21-4A2E-9D91-918C451F40CFQ54566344-64064DDA-A29E-4ECD-8C3C-CB033CFCA07DQ54569512-614336F2-6B94-455D-B029-2689CCBA863FQ55436689-65D609CC-CD9C-4AE9-8585-35CA75B00D99
P2860
Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@ast
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@en
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@nl
type
label
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@ast
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@en
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@nl
prefLabel
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@ast
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@en
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@nl
P2860
P356
P1476
Pulmonary arterial hypertensio ...... e clinical trial meta-analyses
@en
P2093
Alessandra Manes
P2860
P304
P356
10.1093/EURHEARTJ/EHQ152
P577
2010-05-26T00:00:00Z